Breaking News
December 15, 2018 - Cancer Research UK and AstraZeneca open new Functional Genomics Centre
December 15, 2018 - New research lays out potential path for treatment of Huntington’s disease
December 15, 2018 - Prestigious R&D 100 Award presented to Leica Microsystems
December 15, 2018 - Study shows septin proteins detect and kill gut pathogen, Shigella
December 15, 2018 - Study sheds new light on disease-spreading mosquitoes
December 15, 2018 - 2017 Saw Slowing in National Health Care Spending
December 15, 2018 - Monitoring movement reflects efficacy of mandibular splint
December 15, 2018 - Study supports BMI as useful tool for assessing obesity and health
December 15, 2018 - Self-guided, internet-based therapy platforms effectively reduce depression
December 15, 2018 - Organically farmed food has bigger climate impact than conventional food production
December 15, 2018 - Faster, cheaper test has potential to enhance prostate cancer evaluation
December 15, 2018 - Researchers study abnormal blood glucose levels of patients after hospital discharge
December 15, 2018 - Swedish scientists explore direct association of dementia and ischemic stroke deaths
December 15, 2018 - Study finds 117% increase in number of dementia sufferers in 26 years
December 15, 2018 - Eczema Can Drive People to Thoughts of Suicide: Study
December 15, 2018 - Link between neonatal vitamin D deficiency and schizophrenia confirmed
December 15, 2018 - Nurse denied life insurance because she carries naloxone
December 15, 2018 - Ritalin drug affects organization of pathways that build brain networks used in attention, learning
December 15, 2018 - Research pinpoints two proteins involved in creation of stem cells
December 15, 2018 - Gut bacteria may modify effectiveness of anti-diabetes drugs
December 15, 2018 - How often pregnant women follow food avoidance strategy to prevent allergy in offspring?
December 15, 2018 - Using machine learning to predict risk of developing life-threatening infections
December 15, 2018 - How imaginary friends could boost children’s development
December 15, 2018 - Folate deficiency creates more damaging chromosomal abnormalities than previously known
December 15, 2018 - Study provides new insights into molecular mechanisms underlying role of amyloid in Alzheimer’s disease
December 15, 2018 - For the asking, a check is in the mail to help pay for costly drugs
December 15, 2018 - UA scientists uncover biological processes leading to rare brain disorder in babies
December 15, 2018 - The largest database on industrial poisons
December 15, 2018 - ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients
December 15, 2018 - Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
December 15, 2018 - Left ventricular noncompaction – Genetics Home Reference
December 15, 2018 - Children’s sleep not significantly affected by screen time, new study finds
December 15, 2018 - When should dementia patients stop driving? A new guidance for clinicians
December 15, 2018 - Researchers use INTEGRA’s VIAFLO 96/384 to streamline the experimental workflow
December 15, 2018 - Researchers discover protein involved in nematode stress response
December 15, 2018 - Cancer patients have greater risk of developing shingles, study shows
December 14, 2018 - UAlberta scientists identify biomarkers for detecting Alzheimer’s disease in saliva samples
December 14, 2018 - Study uncovers link between tube travel and spread of flu-like illnesses
December 14, 2018 - Caffeine plus another compound in coffee may fight Parkinson’s disease
December 14, 2018 - GW researchers review studies on treatments for prurigo nodularis
December 14, 2018 - Lack of peds preventive care ups unplanned hospital admissions
December 14, 2018 - Miscarriage: When Language Deepens Pain
December 14, 2018 - New method helps better understand pathological development of ALS
December 14, 2018 - Intellectually active lifestyle confers protection against neurodegeneration in Huntington’s patients
December 14, 2018 - Mammalian collagen nanofibrils become stronger and tougher with exercise
December 14, 2018 - Considerable Morbidity, Mortality Due to Animal Encounters
December 14, 2018 - Researchers find inhibiting one protein destroys toxic clumps seen in Parkinson’s disease
December 14, 2018 - How early physical therapy can lessen the long-term need for opioids
December 14, 2018 - Depression, suicide rates highest in Mountain West states
December 14, 2018 - New model could cure the potential to underestimate how quickly diseases spread
December 14, 2018 - Exercise-induced hormone activates cells critical for bone remodeling in mice
December 14, 2018 - Researchers discover new mechanism behind spread of malignant pleural mesothelioma
December 14, 2018 - Health Tip: Celebrate a Healthier Holiday
December 14, 2018 - Scalpel-free surgery enhances quality of life for Parkinson’s patients, study finds
December 14, 2018 - Early physical therapy can reduce risk, amount of long-term opioid use | News Center
December 14, 2018 - Genetic marker, predictor of early relapse in common childhood cancer discovered
December 14, 2018 - Study could lead to a potential new way of treating sepsis
December 14, 2018 - New protein complex helps embryonic stem cells to maintain their indefinite potential
December 14, 2018 - Salk professor receives $1.8 million from NOMIS Foundation for research on mechanisms to promote health
December 14, 2018 - New discovery will improve the safety and predictability of CRISPR
December 14, 2018 - Geneticists discover how sex-linked disorders arise
December 14, 2018 - New method to visualize small-molecule interactions inside cells
December 14, 2018 - Study describes mechanism that makes people more vulnerable to hunger-causing stimuli
December 14, 2018 - Chronic opioid therapy associated with increased healthcare spending and hospital stays
December 14, 2018 - Blood Types
December 14, 2018 - Obesity linked to increased risk of early-onset colorectal cancer
December 14, 2018 - Blood test helps identify distinct molecular signatures in children with cystic fibrosis
December 14, 2018 - In California, doctors accused of sexual misconduct often get second chances
December 14, 2018 - Scientists use water to track electrical activity of nerve cells
December 14, 2018 - Recurrence of urinary tract infection may depend on bacterial strain, study shows
December 14, 2018 - GBT Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for the Treatment of Sickle Cell Disease and GBT Plans to Submit New Drug Application (NDA)
December 14, 2018 - Partial Thromboplastin Time (PTT) Test: MedlinePlus Lab Test Information
December 14, 2018 - Common tactics for health promotion at work may be detrimental to employees with obesity
December 14, 2018 - Myths about migration and health not supported by available evidence
December 14, 2018 - Recent findings on rare genetic disorder may help develop new treatment options
December 14, 2018 - New drug shows promise in treating sarcomas
December 14, 2018 - Scientists perform lung lavage as new approach for tuberculosis diagnosis in rhinoceros
December 14, 2018 - Answering the Biggest Neurological Research Questions of Today
December 14, 2018 - Recent winners of the Nobel Medicine Prize
December 14, 2018 - KHN’s ‘What the Health?’ Insurance enrollment is lagging — and there are lots of reasons why
Beta 2 Microglobulin (B2M) Tumor Marker Test: MedlinePlus Lab Test Information

Beta 2 Microglobulin (B2M) Tumor Marker Test: MedlinePlus Lab Test Information

image_pdfDownload PDFimage_print

What is a beta-2 microglobulin tumor marker test?

This test measures the amount of a protein called beta-2 microglobulin (B2M) in the blood, urine, or cerebrospinal fluid (CSF). B2M is a type of tumor marker. Tumor markers are substances made by cancer cells or by normal cells in response to cancer in the body.

B2M is found on the surface of many cells and is released into the body. Healthy people have small amounts of B2M in their blood and urine.

  • People with cancers of the bone marrow and blood often have high levels of B2M in their blood or urine. These cancers include multiple myeloma, lymphoma, and leukemia.
  • High levels of B2M in cerebrospinal fluid can mean that cancer has spread to the brain and/or spinal cord.

A B2M tumor marker test is not used to diagnose cancer. But it can provide important information about your cancer, including how serious it is and how it may develop in the future.

Other names: total beta-2 microglobulin, β2-microglobulin, B2M

What is it used for?

A beta-2 microglobulin tumor marker test is most often given to people who have been diagnosed with certain cancers of the bone marrow or blood. The test may be used to:

  • Figure out the severity of cancer and whether it has spread. This process is known as cancer staging. The higher the stage, the more advanced the cancer is.
  • Predict disease development and guide treatment.
  • See if cancer treatment is effective.
  • See if cancer has spread to the brain and spinal cord.

Why do I need a beta-2 microglobulin tumor marker test?

You may need this test if you have been diagnosed with multiple myeloma, lymphoma, or leukemia. The test can show the stage of your cancer and whether your cancer treatment is working.

What happens during a beta-2 microglobulin tumor marker test?

A beta-2 microglobulin test is usually a blood test, but may also be given as a 24-hour urine test, or as a cerebrospinal fluid (CSF) analysis.

For a blood test, a health care professional will take a blood sample from a vein in your arm, using a small needle. After the needle is inserted, a small amount of blood will be collected into a test tube or vial. You may feel a little sting when the needle goes in or out. This usually takes less than five minutes.

For a 24-hour urine sample, your health care provider or a laboratory professional will give you a container to collect your urine and instructions on how to collect and store your samples. A 24-hour urine sample test usually includes the following steps:

  • Empty your bladder in the morning and flush that urine away. Record the time.
  • For the next 24 hours, save all your urine in the container provided.
  • Store your urine container in the refrigerator or a cooler with ice.
  • Return the sample container to your health provider’s office or the laboratory as instructed.

For a cerebrospinal fluid (CSF) analysis, a sample of spinal fluid will be collected in a procedure called a spinal tap (also known as a lumbar puncture). A spinal tap is usually done in a hospital. During the procedure:

  • You will lie on your side or sit on an exam table.
  • A health care provider will clean your back and inject an anesthetic into your skin, so you won’t feel pain during the procedure. Your provider may put a numbing cream on your back before this injection.
  • Once the area on your back is completely numb, your provider will insert a thin, hollow needle between two vertebrae in your lower spine. Vertebrae are the small backbones that make up your spine.
  • Your provider will withdraw a small amount of cerebrospinal fluid for testing. This will take about five minutes.
  • You’ll need to stay very still while the fluid is being withdrawn.
  • Your provider may ask you to lie on your back for an hour or two after the procedure. This may prevent you from getting a headache afterward.

Will I need to do anything to prepare for the test?

You don’t need any special preparations for a blood or urine test.

You don’t need any special preparations for a CSF analysis, but you may be asked to empty your bladder and bowels before the test.

Are there any risks to the test?

There is very little risk to having a blood or urine test. After a blood test, you may have slight pain or bruising at the spot where the needle was put in, but most symptoms go away quickly.

There is very little risk to having a spinal tap. You may feel a little pinch or pressure when the needle is inserted. After the test, you may get a headache, called a post-lumbar headache. About one in ten people will get a post-lumbar headache. This can last for several hours or up to a week or more. If you have a headache that lasts longer than several hours, talk to your health care provider. He or she may be able to provide treatment to relieve the pain. You may feel some pain or tenderness in your back at the site where the needle was inserted. You may also have some bleeding at the site.

What do the results mean?

If the test was used to find out how advanced your cancer is (cancer stage), the results may show how much cancer is in your body and whether it is likely to spread.

If the B2M test was used to check how well your treatment is working, your results may show:

  • Your B2M levels are increasing. This may mean your cancer is spreading, and/or your treatment is not working.
  • Your B2M levels are decreasing. This may mean your treatment is working.
  • Your B2M levels have not increased or decreased. This may mean your disease is stable.
  • Your B2M levels decreased, but then later increased. This may mean your cancer has come back after you’ve been treated.

If you have questions about your results, talk to your health care provider.

Is there anything else I need to know about a beta-2 microglobulin tumor marker test?

Beta-2 microglobulin tests are not always used as tumor marker tests for cancer patients. B2M levels are sometimes measured to:

  • Check for kidney damage in people with kidney disease.
  • Find out if a viral infection, such as HIV/AIDS, has affected the brain and/or spinal cord.
  • Check to see if disease has advanced in people with multiple sclerosis, a chronic disease affecting the brain and spinal cord.
Tagged with:

About author

Related Articles